2018 Genitourinary Cancers Symposium Merit Award Winners

2018 Genitourinary Cancers Symposium Merit Award Winners

Merit Awards are awarded to fellows/oncology trainees whose research is addressed in high-quality abstracts submitted to an ASCO-sponsored or cosponsored meeting and recognized for its scientific merit. For more information on the Merit Awards program or instructions on how to apply, visit us online.

The following individuals were selected for a 2018 Genitourinary Cancers Symposium Merit Award:

Bimal Bhindi, MD, CM, MSc, FRCSC
Mayo Clinic
Abstract 704: The probability of indolent versus aggressive histology based on renal tumor size: Implications for surveillance and treatment.

Dominick Bosse, MD
Dana-Farber Cancer Institute
Abstract 626: Genomic alterations to refine prognostication of patients with metastatic renal cell carcinoma.

Jad Chahoud, MD
UT MD Anderson Cancer Center
Abstract 559: Glypican 3 (GPC3) expression in a lethal subgroup of refractory cisplatin-resistant testicular germ cell tumor.

Michal Chovanec, MD, PhD, BA
Comenius University, National Cancer Institute
Abstract 549: Long-term sexual functioning in germ-cell tumor survivors.

Izak Faiena, MD
David Geffen School of Medicine at the University of California, Los Angeles
Abstract 653: A phase I, open-label, dose-escalation and cohort expansion study evaluating the safety and immune response to autologous dendritic cells transduced with AdGMCA9 in patients with metastatic renal cell carcinoma.

Karthik Giridhar, BS, MD
Mayo Clinic
Abstract 249: Prognostic value of chromogranin-a (CGA) compared to circulating tumor cells (CTCs) in metastatic castration resistant prostate cancer (mCRPC).

Hanan Goldberg, MD
Princess Margaret Cancer Center
Abstract 177: Can free PSA be used as a biomarker in biochemical recurrence after surgery to predict castrate resistant prostate cancer?

Jeffrey Graham, MD
Tom Baker Cancer Centre, University of Calgary
Abstract 581: Cytoreductive nephrectomy in metastatic papillary renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).

Anis Hamid, MBBS
Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute
Abstract 184: Tumor suppressor aberrations and outcomes in localized and metastatic hormone sensitive prostate cancer (PrCa).

William Hwang, MD, PhD
Massachusetts General Hospital
Abstract 24: Optimal timing of post-prostatectomy radiotherapy for prostate cancer with high-risk pathologic features: A multi-institutional analysis.

Daniel Khalaf, MD
British Columbia Cancer Agency - Vancouver Centre
Abstract 260: Determining biomarkers of response to docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC) using circulating cell-free tumor DNA (ctDNA).

Edmond Kwan, MBBS
Monash Health
Abstract 252: Whole blood AR-V7 and AR-V9 mRNA expression and treatment response in metastatic castrate-resistant prostate cancer (mCRPC).

Rebeca Lozano, MD
Spanish National Cancer Research Centre
Abstract 164: Comparative assessment of abiraterone or enzalutamide activity in the PROREPAIR-B study.

Deaglan McHugh, BA, MRCP
Memorial Sloan Kettering Cancer Center
Abstract 567: Adjuvant etoposide plus cisplatin (EP) for pathologic stage (PS) II nonseminomatous germ cell tumor (NSGCT).

Marina Milic, MD, MSc
Mount Vernon Cancer Centre

Abstract 558: A qualitative analysis of the impact of Carboplatin AUC 10 on physical, work functioning, and bone marrow toxicity, in patients with metastatic seminoma: A single centre experience.

Pavlos Msaouel, MD, PhD
UT MD Anderson Cancer Center
Abstract 614: Effect of SMARCB1 deficiency in renal medullary carcinoma (RMC) on genes associated with nucleosome assembly and telomere organization.

Lucia Nappi, MD
Vancouver Prostate Centre and SWOG AYA, Prevention and Surveillance and SWOG YI Award
Abstract 569: Plasma miR371 for the detection of viable germ cell tumor in testicular cancer patients with enlarging or post chemotherapy residual nodes.

Patrick Pilie, MD
UT MD Anderson Cancer Center
Abstract 585: Homologous repair deficiency in VHL-mutated clear cell renal cell carcinoma.

Irbaz Bin Riaz, MBBS, MS
Mayo Clinic
Abstract 243: Abiraterone acetate (AA) or docetaxel (D) in metastatic castration-sensitive prostate cancer (mCSPC): A systematic review and network meta-analysis of randomized clinical trials (RCTs).

Minke Smits, MBBS
Radboud University Nijmegen Medical Center
Abstract 248: Immunological and genomic correlates of response to anti-PD1 checkpoint therapy in mismatch proficient and deficient patients with metastasized castration resistant prostate cancer.

Mohamad Sonbol, MD
Mayo Clinic
Abstract 689: Adjuvant antiangiogenic agents in post-nephrectomy renal cell carcinoma (RCC): A systematic review and meta-analysis.

Claudio Vernieri, MD, PhD
Fondazione IRCCS Istituto Nazionale dei Tumori
Abstract 617: Prognostic and predictive role of fumarate hydratase in metastatic clear cell renal cell carcinoma.

Harm Westdorp, MSc
Radboud University Nijmegen Medical Center
Abstract 219: Myeloid and plasmacytoid dendritic cell vaccinations for castration-resistant prostate cancer patients.

Steven Yip, MD
BC Cancer Agency Vancouver Cancer Centre
Abstract 242: Outcomes in patients (Pts) with advanced prostate cancer and inactivating germline mutations in BRCA2 or ATM.